Immunohistochemical analysis of nm23 protein expression in malignant bone tumors

Yoshinao Oda, Hajo Walter, Kathrin Radig, Ingeborg Röse, Wolfram Neumann, Albert Roessner

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Expression levels of nm23 protein in 72 malignant bone tumors comprising 41 osteosarcomas, 22 chondrosarcomas, 6 Ewing's sarcomas, and 2 malignant fibrous histiocytomas were examined immunohistochemically, using anti-nm23 protein polyclonal antibody, and compared with 51 cases of benign bone tumors or tumor-like lesions. Malignant bone tumors showed significantly higher nm23 protein expression than benign bone tumors or tumor-like lesions (P<0.0001). In chondrosarcoma, nm23 expression increased in high-grade tumors (grade I versus grade II and III:P=0.0229). In the cases of osteosarcoma, however, grade IV osteosarcomas showed decreased expression of nm23 compared with grade III tumors (P=0.0122). There was no significant relationship between nm23 expression and histological type. nm23 expression had no correlation with metastatic potential in osteosarcoma, although the therapy was not uniform in our cases. Furthermore, in 6 cases of osteosarcoma and 1 case of Ewing's sarcoma, there was no clear tendency for a decrease of nm23 in the metastatic sites compared with primary sites, as reported in breast cancer. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma.

Original languageEnglish
Pages (from-to)667-673
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume121
Issue number11
DOIs
Publication statusPublished - Nov 1 1995
Externally publishedYes

Fingerprint

Osteosarcoma
Bone and Bones
Neoplasms
Proteins
Chondrosarcoma
Ewing's Sarcoma
Breast Neoplasms
Malignant Fibrous Histiocytoma
Theoretical Models
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Immunohistochemical analysis of nm23 protein expression in malignant bone tumors. / Oda, Yoshinao; Walter, Hajo; Radig, Kathrin; Röse, Ingeborg; Neumann, Wolfram; Roessner, Albert.

In: Journal of Cancer Research and Clinical Oncology, Vol. 121, No. 11, 01.11.1995, p. 667-673.

Research output: Contribution to journalArticle

Oda, Yoshinao ; Walter, Hajo ; Radig, Kathrin ; Röse, Ingeborg ; Neumann, Wolfram ; Roessner, Albert. / Immunohistochemical analysis of nm23 protein expression in malignant bone tumors. In: Journal of Cancer Research and Clinical Oncology. 1995 ; Vol. 121, No. 11. pp. 667-673.
@article{26c0eec11f604fa7a5e479d0fe069812,
title = "Immunohistochemical analysis of nm23 protein expression in malignant bone tumors",
abstract = "Expression levels of nm23 protein in 72 malignant bone tumors comprising 41 osteosarcomas, 22 chondrosarcomas, 6 Ewing's sarcomas, and 2 malignant fibrous histiocytomas were examined immunohistochemically, using anti-nm23 protein polyclonal antibody, and compared with 51 cases of benign bone tumors or tumor-like lesions. Malignant bone tumors showed significantly higher nm23 protein expression than benign bone tumors or tumor-like lesions (P<0.0001). In chondrosarcoma, nm23 expression increased in high-grade tumors (grade I versus grade II and III:P=0.0229). In the cases of osteosarcoma, however, grade IV osteosarcomas showed decreased expression of nm23 compared with grade III tumors (P=0.0122). There was no significant relationship between nm23 expression and histological type. nm23 expression had no correlation with metastatic potential in osteosarcoma, although the therapy was not uniform in our cases. Furthermore, in 6 cases of osteosarcoma and 1 case of Ewing's sarcoma, there was no clear tendency for a decrease of nm23 in the metastatic sites compared with primary sites, as reported in breast cancer. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma.",
author = "Yoshinao Oda and Hajo Walter and Kathrin Radig and Ingeborg R{\"o}se and Wolfram Neumann and Albert Roessner",
year = "1995",
month = "11",
day = "1",
doi = "10.1007/BF01218525",
language = "English",
volume = "121",
pages = "667--673",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Immunohistochemical analysis of nm23 protein expression in malignant bone tumors

AU - Oda, Yoshinao

AU - Walter, Hajo

AU - Radig, Kathrin

AU - Röse, Ingeborg

AU - Neumann, Wolfram

AU - Roessner, Albert

PY - 1995/11/1

Y1 - 1995/11/1

N2 - Expression levels of nm23 protein in 72 malignant bone tumors comprising 41 osteosarcomas, 22 chondrosarcomas, 6 Ewing's sarcomas, and 2 malignant fibrous histiocytomas were examined immunohistochemically, using anti-nm23 protein polyclonal antibody, and compared with 51 cases of benign bone tumors or tumor-like lesions. Malignant bone tumors showed significantly higher nm23 protein expression than benign bone tumors or tumor-like lesions (P<0.0001). In chondrosarcoma, nm23 expression increased in high-grade tumors (grade I versus grade II and III:P=0.0229). In the cases of osteosarcoma, however, grade IV osteosarcomas showed decreased expression of nm23 compared with grade III tumors (P=0.0122). There was no significant relationship between nm23 expression and histological type. nm23 expression had no correlation with metastatic potential in osteosarcoma, although the therapy was not uniform in our cases. Furthermore, in 6 cases of osteosarcoma and 1 case of Ewing's sarcoma, there was no clear tendency for a decrease of nm23 in the metastatic sites compared with primary sites, as reported in breast cancer. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma.

AB - Expression levels of nm23 protein in 72 malignant bone tumors comprising 41 osteosarcomas, 22 chondrosarcomas, 6 Ewing's sarcomas, and 2 malignant fibrous histiocytomas were examined immunohistochemically, using anti-nm23 protein polyclonal antibody, and compared with 51 cases of benign bone tumors or tumor-like lesions. Malignant bone tumors showed significantly higher nm23 protein expression than benign bone tumors or tumor-like lesions (P<0.0001). In chondrosarcoma, nm23 expression increased in high-grade tumors (grade I versus grade II and III:P=0.0229). In the cases of osteosarcoma, however, grade IV osteosarcomas showed decreased expression of nm23 compared with grade III tumors (P=0.0122). There was no significant relationship between nm23 expression and histological type. nm23 expression had no correlation with metastatic potential in osteosarcoma, although the therapy was not uniform in our cases. Furthermore, in 6 cases of osteosarcoma and 1 case of Ewing's sarcoma, there was no clear tendency for a decrease of nm23 in the metastatic sites compared with primary sites, as reported in breast cancer. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0028886998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028886998&partnerID=8YFLogxK

U2 - 10.1007/BF01218525

DO - 10.1007/BF01218525

M3 - Article

C2 - 7593131

AN - SCOPUS:0028886998

VL - 121

SP - 667

EP - 673

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 11

ER -